meta
|
evidence
oncology
Living systematic review and meta-analysis
refractory classic Hodgkin lymphoma (R/R cHL)
R/R cHL - second line or more (L2)
1
colorectal cancer (CRC)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus cometinib
pembrolizumab based treatment
pembrolizumab alone
Immune checkpoint association
durvalumab plus tremelimumab